Reduced-intensity conditioning (RIC) permits allogeneic hematopoietic progenitor cell transplantation in patients who would not be considered candidates for transplantation using a myeloablative preparative regimen because of age, comorbidities or prior therapy. In the setting of myeloablative transplantation, use of antithymocyte globulin (ATG) can reduce the risk of GVHD without negatively affecting transplant outcomes; however, limited data exist on the impact of ATG in the setting of RIC, particularly when there is HLA-mismatch. We performed a retrospective analysis of 85 patients who received unrelated donor transplants at our institution for hematologic malignancies following conditioning with fludarabine and melphalan (FluMel), with or without rabbit ATG (6 mg/kg). ATG was targeted to patients receiving HLA-mismatched grafts. With a median follow-up of 36 months, those receiving ATG and a mismatched graft had similar rates of acute and chronic GVHD, relapse, and similar OS compared with those receiving HLA-matched grafts without ATG. In a multivariate analysis, HLA-mismatched donor was not associated with a decrement in OS. We conclude that this intermediate dose of ATG is effective in preventing severe GVHD in the setting of HLA-mismatch, without undue compromise of the graft versus tumor effects on which RIC transplants depend.
INTRODUCTION
Allogeneic hematopoietic cell transplantation is potentially a curative therapy for many patients with otherwise intractable hematologic malignancies. The incidence of most hematologic malignancies increases with age, which excludes a substantial fraction of patients from consideration for transplantation using a myeloablative conditioning regimen. Over the past decade, numerous studies have demonstrated the feasibility and efficacy of transplantation following reduced-intensity conditioning (RIC) for older patients and those with significant comorbidities. [1] [2] [3] [4] [5] In principle, use of a RIC reduces immediate toxicities of the transplant maneuver, but the patient remains subject to morbidity and mortality associated with GVHD. 6 The ultimate efficacy of the transplant therefore depends on successful achievement of a balance between graft versus tumor effects necessary for eradication of the malignancy and complications associated with GVHD and immune incompetence. 7 The best outcomes with allogeneic transplantation are achieved through transplantation of hematopietic progenitor cells from an HLA-matched related or unrelated donor; however, even in this setting grades II-IV acute GVHD (aGVHD) occur in 30-50% of patients. 6, 8 Further, for any degree of HLA disparity, OS generally decreases as a consequence of nonrelapse mortality from GVHD and complications arising from its management. 9, 10 The use of antithymocyte globulin (ATG) as in vivo T-cell depletion for the prevention of GVHD has been studied in the unrelated donor (URD) transplant setting, primarily following myeloablative conditioning. Given concurrently with myeloablative conditioning, ATG may reduce the risk of severe acute and chronic GVHD, but often at the cost of higher rates of opportunistic infection and/or relapse. [11] [12] [13] [14] In contrast, for patients receiving a RIC followed by a T-cell replete graft, a recent analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR) suggested that inclusion of pre-transplant ATG resulted in inferior survival. 15 These results must be interpreted cautiously given the heterogeneity of conditioning regimens, preparations of ATG and other differences inherent in analysis of registry data. In an effort to study this question further, we have performed a single institution retrospective analysis of a consecutive series of patients with hematologic malignancies who received URD transplants following a uniform RIC regimen of fludarabine and melphalan (FluMel). We specifically compared outcomes of patients who received pre-transplant ATG in the setting of HLA-mismatch with those of patients who received an HLA-matched URD graft without ATG.
PATIENTS AND METHODS

Patient characteristics
This is an IRB approved retrospective analysis of consecutive patients with hematologic malignancies who underwent allo-SCT from URDs following conditioning with FluMel with or without ATG at Emory University Hospital between May 2004 and December 2011. Baseline data on the transplant maneuver and post-transplant outcomes were extracted from the institutional transplant database and the individual medical record of each patient.
Between May 2004 and December 2011, 95 patients received FluMel conditioning before URD transplantation for hematologic malignancies. Ten patients were eliminated from this analysis for the following reasons: three patients were enrolled on a clinical trial of alternative GVHD prophylaxis and seven received HLA-mismatched transplants without the use of pre-transplant ATG. Patient characteristics of the remaining 85 patients included in the analysis are detailed in Table 1 . Median age, graft source, disease status and CMV status were similar for the group that received ATG and the group that did not. Patients with high-risk disease at the time of transplantation were similarly represented in the two groups, and most patients had received extensive prior cytotoxic therapy. Fifteen patients had undergone prior autologous or allogeneic transplantation, including ten in the FluMel group and five in the FluMel-ATG group. Of the 14 patients in this series under the age of 40 years, reasons for the use of a RIC regimen included prior myeloablative autologous or allogeneic transplant (six patients), significant comorbidities (five patients) and lowgrade lymphoma (three patients). The predominant stem cell source was G-CSF-stimulated blood progenitor cells, and grafts contained a median of 11.6 and 11.0 Â 10 6 CD34 þ cells/kg recipient weight for FluMel and FluMel-ATG patients, respectively.
Donor-recipient HLA matching
All donor-recipient pairs had high resolution sequence-based typing at HLA-A, B, C, DRB1 and DQB1 loci. Thirty-one (36%) of the 85 patients received grafts from donors who were mismatched at one or two loci, based on high resolution sequence-based typing at HLA-A, B, C, DRB1 and DQB1. All patients who received a less than 10/10-matched graft received ATG. If we consider only matching at HLA-A, B, C and DRB1, 8 (26%) of the ATG patients received an 8/8-matched graft, 19 (61%) received a 7/8 match and 4 (13%) received a 6/8 match.
Conditioning, GVHD prophylaxis and supportive care
All patients were treated with fludarabine 100 mg/m 2 (25 mg/m 2 on days À 6, À 5, À 4, À 3) and melphalan 140 mg/m 2 (70 mg/m 2 on days À 3, À 2), followed by a day of rest before infusion of the stem cell product on day 0. Ex vivo T-cell depletion or cell selection of the graft was not employed. As per our standard institutional practice, patients receiving grafts from HLA-mismatched URDs were assigned by the treating physician to receive ATG (Thymoglobulin, Genzyme, Cambridge, MA, USA) 6 mg/kg as additional GVHD prophylaxis. ATG was given on the schedule: 0.5 mg/kg on day À 5, 1.0 mg/kg on day À 4, and 1.5 mg/kg on days À 3, À 2, À 1. Post-transplant immunosuppression was at the discretion of the treating physician, but the majority of patients were assigned to receive tacrolimus or CYA plus either MTX (15 mg/m 2 on day 1, 10 mg/m 2 on days 3, 6, 11) or mycophenolate mofetil (15 mg/kg BID on days 0 through 30); outcome analyses are based on intent-to-treat. Patients received conditioning, transplantation and early post-transplant care on a HEPA-filtered inpatient unit, and received antimicrobials, transfusion support and other routine supportive care per institutional guidelines. Post-transplant growth factors were not routinely utilized. All patients were monitored weekly for CMV reactivation by blood PCR until at least day 100 post-transplant, and preemptive antiviral therapy was given for confirmed evidence of CMV replication in the blood.
Data collection and statistical analysis
Basic demographic data and pre-transplant medical information regarding donors and patients were abstracted from the medical records and the institutional BMT database. Patients were categorized with respect to disease/disease status just before transplant as it pertains to the risk of relapse according to the scheme outlined by Kahl et al. 16 Post-transplant data were collected including time to neutrophil and platelet recovery (per CIBMTR criteria), incidence of CMV reactivation, incidence and grade of acute and chronic GVHD (according to NIH consensus criteria), disease response, relapse, nonrelapse mortality and donor-recipient chimerism by wither FISH (XY) or VNTR analysis. The probability of OS was estimated with the use of the Kaplan-Meier method, and survival curves were compared using the log-rank test. Survival time was defined as the time from the date of transplantation to the date of death or date of last contact. Probabilities of aGVHD, cGVHD, nonrelapse mortality and relapse were estimated with the use of cumulative incidence curves to account for competing risks. 17 Serum creatinine at the time of transplantation, Karnofsky performance scores and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) scores 18 were also compared between groups to examine potential selection bias, particularly between those patients who received MTX versus mycophenolate mofetil as GVHD prophylaxis.
RESULTS
Hematologic engraftment
With the exception of two patients (both of whom received ATG) who both died on day 10 post transplant (one with multiorgan failure and one with sepsis syndrome), all patients achieved neutrophil and platelet engraftment, at a median of 15 and 19 days, respectively. There were no differences in time to engraftment for FluMel versus FluMel-ATG patients. All patients surviving until day 100 (69 of 85 patients) achieved 100% donor engraftment in blood T-cell and -marrow compartments. Late graft failure occurred in two FluMel patients, both of whom retained full donor chimerism; one received a successful second infusion of donor cells and the other spontaneously recovered hematopoietic function over time. GVHD Grades 2-4 acute GVHD occurred in 24 (44%) of the FluMel patients and 13 (45%) of the FluMel-ATG patients at risk. The cumulative incidence of grades 3-4 acute GVHD was also similar in the two groups, as shown in Figure 1 . There was a reduced incidence of grades 3-4 acute GVHD associated with the use of MTX as part of GVHD prophylaxis (13% versus 31%, P ¼ 0.037). There were not significant differences in baseline renal or hepatic function among patients who were assigned to receive MTX versus other prophylaxis; however, patients assigned to nonMTX containing regimens were more likely to have a Karnofsky performance status of o90% (data not shown). Among There was no difference in the incidence of chronic GVHD for patients assigned to MTX versus other regimens for GVHD prophylaxis.
Immune reconstitution and infection CD4 counts at 3 months, 6 months and 1 year post transplant showed evidence of a significant delay in immune reconstitution among patients receiving ATG, as shown in Figure 2 . NRM, relapse and survival Table 2 enumerates causes of death for the 43 patients who had died at the time of last follow-up. GVHD and infection were the primary causes of nonrelapse mortality, but GVHD was a slightly more common cause of death among FluMel patients than FluMel-ATG patients. Relapse has occurred in 10 FluMel patients and five FluMel-ATG patients, and 10 of the 15 relapsed patients had died at the time of last follow-up. The cumulative incidence of relapse was similar for the FluMel and FluMel-ATG groups, as shown in Figure 3 , and the pretransplant disease risk category was highly predictive of relapse. At 3 years post transplant, the cumulative incidence of relapse estimates were 0% for patients in the low relapse risk category, 22% for standard risk patients and 41% for patients in the high risk groups. Although subsets are small, the 3-year cumulative incidence of relapse estimates for FluMel versus FluMel-ATG were 15% and 33%, respectively, for standard risk patients (P ¼ NS); among high risk patients, 3-year cumulative incidence of relapse estimates were 47% and 31%, respectively (P ¼ NS). In a multivariate model adjusting for disease risk category, there was no association between use of ATG and the risk of relapse. 
Survival
In this population of older and/or heavily pre-treated patients with high-risk hematologic malignancies, 1-and 3-year OS rates for the entire group were 67% and 46%, respectively, with a median follow-up of 36 months for surviving patients. Early mortality (death within 100 days of transplant) occurred in 10 patients (19%) in the FluMel and six patients (19%) in the FluMel-ATG group and was due to nonrelapse causes in all but one case. Most importantly, patients who received ATG because of HLA-mismatch had similar long-term OS ( Figure 4 ) and progression-free survival compared with the group who received matched grafts and no ATG. A multivariate analysis of OS was performed using the variables of disease risk category, CMV serostatus, recipient age, marrow versus peripheral blood graft, mismatch/ATG and use of MTX as part of GVHD prophylaxis. Variables associated with allcause mortality included disease risk category (HR: 1.75, 95% CI: 1.05-2.95), assignment to GVHD prophylaxis that included MTX (HR: 0.23, 95% CI: 0.11-0.52), and increasing age (HR: 1.03 for each year, 95% CI: 1.006-1.061). There was also a trend toward increased mortality associated with a pre-transplant Karnofsky performance score o90% (HR: 2.0, 95% CI: 0.97-4.11). In this series, there was no association between mismatch/ATG and OS.
DISCUSSION
We examined outcomes in a cohort of patients undergoing URD SCT following the RIC regimen of fludarabine and melphalan, with the use of an intermediate dose of rabbit ATG targeted to patients with one or two HLA mismatches at the ag or allele level. In our series, this dose of ATG appeared to prevent the severe GVHD and mitigate the decrease in OS typically seen in patients transplanted with HLA disparate stem cell grafts. 10 The utility of pre-transplant ATG as part of GVHD prophylaxis in patients receiving URD transplants has been debated for many years, and while the use of ATG appears to reduce the incidence of GVHD, benefits in terms of OS are less clear. [11] [12] [13] [14] 19 Further, both the preparation and dose of ATG appear to be important determinants of its impact on post-transplant outcomes. For rabbit ATG (Thymoglobulin), an early multicenter prospective study conducted by the GITMO group suggested that while a dose of 15 mg/kg was associated with a significant reduction in the risk of severe (grades III-IV) GVHD, this benefit was counterbalanced by an increased risk of opportunistic infections, resulting in similar OS for ATG and placebo groups. 11 A more recent study explored a range of doses of rabbit ATG and observed that doses of 6 and 8 mg/kg were associated with the best OS outcomes, successfully balancing the competing risks of aGVHD and opportunistic infections. 12 In a retrospective single institution analysis, Pidala et al.
14 reported very promising results using a dose of 7.5 mg/kg in the setting of mismatched URD transplantation, with only an 11% incidence of grade III-IV acute GVHD and an 11% risk of early nonrelapse mortality in this high-risk setting. In another retrospective cohort study, Hamadani et al. 20 observed a reduction in the risk of infection and nonrelapse mortality without a concomitant increase in GVHD upon lowering the ATG dose from 7.5 to 6 mg/kg, specifically in the setting of RIC . Finally, Crocchiolo et al. 21 did a large retrospective analysis comparing doses of 2.5 and 5 mg/kg of ATG, and they showed a reduction in both acute and chronic GVHD with only a minor increase in the risk of relapse with the higher 5 mg/kg dose. Taken together, these data suggest that intermediate doses of rabbit ATG in the range of 5-8 mg/kg may be optimal. The timing and schedule of ATG during the conditioning regimen may also be important in modulating the degree of immune-suppression that results from the biologically active ATG that remains in the circulation at the time of donor cell infusion. 22 Our results are in sharp contrast with those from a recent report from the CIBMTR examining the impact of pre-transplant anti-Tcell antibodies on outcomes following RIC transplantation for hematologic malignancies. In that analysis, the use of ATG was associated with inferior overall and disease-free survival and an increased risk of disease relapse in comparison with patients who did not receive antibody therapy. 15 It is important to point out that patients receiving equine and rabbit ATG were pooled together in the ATG group, doses of ATG varied according to institutional protocol, and a variety of donor types and conditioning regimens were included, making this a very heterogeneous collection of patients. In contrast, our patients all received a uniform conditioning regimen, URD grafts, and an intermediate dose of ATG that may not be associated with the detrimental impact on immune reconstitution and graft versus tumor effects observed with higher doses.
In our series, the use of MTX as part of GVHD prophylaxis was associated with a lower likelihood of severe acute GVHD and was the variable most strongly associated with OS. There were certainly biases in the assignments to MTX versus mycophenolate mofetil and we did observe an association between assignment to alternate GVHD prophylaxis regimens and poor performance status. Several studies suggest roughly equivalent outcomes for MTX versus mycophenolate mofetil when combined with a calcineurin inhibitor in the setting of matched-related donor transplantation. 23, 24 On the other hand, a recent single center randomized phase II study in which approximately half of patients received a graft from an URD showed a lower incidence of grades III-IV acute GVHD among patients assigned to MTX, and this effect was most pronounced among those receiving URD grafts (26% versus 4%; P ¼ 0.04). 25 We do not draw firm conclusions regarding the effect of MTX from this data set, given the small numbers and potential confounding variables.
In summary, we have analyzed outcomes in a cohort of patients undergoing URD stem cell transplantation with the RIC regimen of fludarabine and melphalan, with an intermediate dose of rabbit ATG for additional GVHD prophylaxis for patients receiving grafts from mismatched donors. The use of ATG appeared to prevent the increased rates of acute and chronic GVHD that would be expected in patients transplanted with HLA disparate stem cell grafts. In addition, although T-cell immune reconstitution was delayed among patients receiving ATG, rates of relapse, serious infections and infectious deaths were roughly similar for the two groups. We observed similar outcomes comparing recipients of HLA-matched and -mismatched URD grafts. We conclude that the combination of fludarabine and melphalan with ATG is an acceptable RIC regimen for use in patients receiving partially matched URD transplants, permitting reliable engraftment and acceptable rates of early and long-term toxicities.
